New drug for relapsed Glioblastoma, a deadly form of brain cancer
There is exciting news on the horizon for glioblastoma, which is a deadly form of brain cancer.
Have you heard of activated T cell therapy?
It is similar to the car-T cell therapies that you often hear about for blood cancers.
Well, this form of therapy is now available for patients with brain cancers.
The catch is, you must enroll in a clinical trial. It is not yet available to the public.
To qualify, one must have glioblastoma, a form of brain cancer , and cancer must have relapsed after the first diagnosis.
Patients who are interested are now able to ask for information about enrolment at the Cedars Sinai Medical Centre in Los Angeles.
This trial will be classified under a Phase one type of clinical trial.
The drug company, Kairos pharma is the sponsor.
This exciting new therapy, otherwise known as KROS 201, is a form of activated T cell therapy. The patient’s white blood cells are first harvested. Blood is removed by a simple intravenous blood draw, and then sent off to the lab to be processed in a cell culture.
In the lab, the white blood cells are primed by exposing them to small protein substances called cytokines. This process will in turn activate the white blood cells, specifically the killer T cells. Once activated, these cells can now fight cancer by inactivating cancer stem cells.
The T cells are returned to the patient’s body by intravenous infusion.
The link for enrolment is not yet available but do keep checking on www.clinicaltrials.gov

